TL-32711 is a Smac mimetic that is currently in clinical trials as a potential treatment for a variety of cancers. TL-32711 inhibits members of the inhibitor of apoptosis protein (IAP) family proteins, inducing degradation of cIAP1 and cIAP2. TL-32711 exhibits anticancer chemotherapeutic activity, inhibiting NF-κB activation and tumor growth in animal models. In acute myelogenous leukemia (AML) cells, this compound induces caspase 8-mediated apoptosis. This compound also improves the efficacy of co-administered antivirals in models of hepatitis B infection.